MGO One Seven LLC Has $11.19 Million Stock Position in Medtronic PLC $MDT

MGO One Seven LLC boosted its holdings in Medtronic PLC (NYSE:MDT) by 16.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 116,505 shares of the medical technology company’s stock after purchasing an additional 16,299 shares during the quarter. MGO One Seven LLC’s holdings in Medtronic were worth $11,191,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Curbstone Financial Management Corp increased its stake in shares of Medtronic by 1.8% in the 4th quarter. Curbstone Financial Management Corp now owns 5,594 shares of the medical technology company’s stock valued at $537,000 after acquiring an additional 100 shares in the last quarter. New England Capital Financial Advisors LLC lifted its position in shares of Medtronic by 7.8% during the 4th quarter. New England Capital Financial Advisors LLC now owns 1,403 shares of the medical technology company’s stock valued at $135,000 after acquiring an additional 101 shares during the period. Baker Tilly Wealth Management LLC boosted its stake in Medtronic by 3.3% during the fourth quarter. Baker Tilly Wealth Management LLC now owns 3,221 shares of the medical technology company’s stock worth $309,000 after acquiring an additional 102 shares in the last quarter. Maseco LLP boosted its stake in Medtronic by 32.1% during the fourth quarter. Maseco LLP now owns 444 shares of the medical technology company’s stock worth $43,000 after acquiring an additional 108 shares in the last quarter. Finally, Holistic Financial Partners grew its holdings in Medtronic by 3.0% in the third quarter. Holistic Financial Partners now owns 3,697 shares of the medical technology company’s stock worth $352,000 after purchasing an additional 109 shares during the period. 82.06% of the stock is owned by institutional investors and hedge funds.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: CE Mark for Stealth AXiS system — Medtronic announced CE Mark clearance for its Stealth AXiS platform (navigation, planning and robotics combined). This expands commercial opportunity in image‑guided surgery in Europe following earlier FDA approval and could accelerate adoption in spine/neurosurgery over the coming quarters. Following FDA Approval, Medtronic (MDT) Receives CE Mark For Stealth AXiS System
• Positive Sentiment: Adaptive DBS launch in India — Medtronic has launched its adaptive deep brain stimulation (aDBS) system for Parkinson’s in India, opening a large, fast‑growing market for neuromodulation and providing more real‑world data and revenue potential from emerging markets. Medtronic Expands Neuromodulation Reach With Adaptive DBS Launch In India
• Positive Sentiment: $20M investment in Orchestra BioMed — Medtronic funded a $20M tranche to Orchestra BioMed to support the BACKBEAT pivotal trial for AVIM therapy; the deal accelerates a partner’s trial execution and secures Medtronic optional exposure to a potential adjunct therapy that complements its pacemaker/CRM portfolio. Financially modest for MDT but strategically relevant. Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement
• Neutral Sentiment: Wall Street consensus remains broadly positive (average brokerage recommendation = Buy) but analysts’ views are mixed on valuation and near‑term upside; investor reaction will depend on whether guidance/earnings beats accelerate top‑line momentum. Is It Worth Investing in Medtronic (MDT) Based on Wall Street’s Bullish Views?
• Negative Sentiment: Shares pulled back amid market gains — coverage notes MDT shares recently fell while the broader market rose, reflecting short‑term profit taking, valuation pressure and technical weakness (trading below key moving averages). That short‑term selling can mute the impact of positive product/partnership news. Medtronic (MDT) Stock Sinks As Market Gains: Here’s Why

Insider Buying and Selling

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the completion of the sale, the executive vice president directly owned 32,768 shares of the company’s stock, valued at approximately $3,201,761.28. The trade was a 61.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.26% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. Piper Sandler decreased their price target on shares of Medtronic from $105.00 to $91.00 and set a “neutral” rating for the company in a research note on Wednesday, April 1st. Barclays increased their price objective on shares of Medtronic from $118.00 to $120.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 1st. Mizuho reduced their target price on Medtronic from $125.00 to $120.00 and set an “outperform” rating for the company in a research note on Monday, April 13th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $95.00 target price on shares of Medtronic in a research report on Thursday, April 23rd. Finally, Citigroup cut their price target on Medtronic from $117.00 to $110.00 and set a “buy” rating on the stock in a report on Tuesday, April 7th. Fifteen equities research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $107.80.

Medtronic Stock Performance

MDT opened at $77.99 on Friday. Medtronic PLC has a 1-year low of $77.16 and a 1-year high of $106.33. The company has a market cap of $100.13 billion, a price-to-earnings ratio of 21.72, a PEG ratio of 1.84 and a beta of 0.62. The company’s fifty day moving average price is $87.26 and its two-hundred day moving average price is $94.43. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last issued its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.34 by $0.02. The firm had revenue of $9.02 billion during the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The business’s revenue was up 5.8% on a year-over-year basis. During the same period last year, the company earned $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, analysts expect that Medtronic PLC will post 5.57 EPS for the current fiscal year.

Medtronic Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, April 17th. Shareholders of record on Friday, March 27th were paid a dividend of $0.71 per share. The ex-dividend date was Friday, March 27th. This represents a $2.84 dividend on an annualized basis and a yield of 3.6%. Medtronic’s payout ratio is 79.11%.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).